ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)

HFCAS OpenIR

	ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
	Cheng, Y.1; Wang, J.2; Cang, S.3; Cao, L.4 ; Chen, E.5; Dong, X.6; Fan, Y.7; Gao, B.8; Guo, Q.9; Huang, D.10; Li, S.11; Liu, A.12; Lv, D.13; Pan, Y.14; Tang, K.15; Yao, W.16; Ye, F.17 ; Yu, Y.18; Zang, A.19; Gao, M.20
	2021-04-01
发表期刊	JOURNAL OF THORACIC ONCOLOGY
ISSN	1556-0864
收录类别	SCI
语种	英语
资助项目	AstraZeneca
项目资助者	AstraZeneca
WOS研究方向	Oncology ; Respiratory System
WOS类目	Oncology ; Respiratory System
WOS记录号	WOS:000634855900061
出版者	ELSEVIER SCIENCE INC
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/121060
专题	中国科学院合肥物质科学研究院
作者单位	1.Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China 2.Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China 3.Henan Prov Peoples Hosp, Zhengzhou, Henan, Peoples R China 4.Univ Sci & Technol China, USTC, Affiliated Hosp 1, Hefei, Anhui, Peoples R China 5.Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China 6.Wuhan Union Hosp, Wuhan, Hubei, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Zhejiang, Peoples R China 8.Ruijin Hosp, Shanghai, Peoples R China 9.Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China 10.Tianjin Lung Canc Ctr, Tianjin, Peoples R China 11.Fudan Univ, Huashan Hosp, Shanghai, Peoples R China 12.Nanchang Univ, Affiliated Hosp 2, Oncol, Nanchang, Jiangxi, Peoples R China 13.Zhejiang Prov Wenzhou Med Univ, Affiliated Taizhou Hosp, Taizhou, Peoples R China 14.Anhui Prov Hosp, USTC, Affiliated Hosp 1, Hefei, Peoples R China 15.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China 16.Sichuan Canc Hosp, Chengdu, Sichuan, Peoples R China 17.Xiamen Univ, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China 18.Harbin Med Univ Canc Hosp, Harbin, Heilongjiang, Peoples R China 19.Hebei Univ, Affiliated Hosp, Baoding, Peoples R China 20.AstraZeneca, Med Affairs, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Cheng, Y.,Wang, J.,Cang, S.,et al. ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)[J]. JOURNAL OF THORACIC ONCOLOGY,2021,16.
APA	Cheng, Y..,Wang, J..,Cang, S..,Cao, L..,Chen, E..,...&Gao, M..(2021).ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC).JOURNAL OF THORACIC ONCOLOGY,16.
MLA	Cheng, Y.,et al."ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)".JOURNAL OF THORACIC ONCOLOGY 16(2021).